Bergisch Gladbach / Cincinnati, September 29, 2009 - Girindus, a leading service provider to the pharmaceutical industry and a dedicated manufacturer of therapeutic oligonucleotides, announces that Girindus Group is not affected by Solvay´s decision to sell its Pharmaceuticals Sector to Abbott. Girindus is a member of Solvay Organics, which is part of the Chemicals Division of the Solvay Group and is therefore completely separate from the Pharmaceuticals Division.
Girindus outstanding knowledge and technical expertise in cGMP manufacturing and process development of oligonucleotides will continue to deliver high quality services to our growing customer base.

Dr. Mark Laskovics, President and Chief Operating Officer of Girindus points out: "We are fully committed to provide our customers with high-level, sustainable chemistry, analytical and CMC services during the development and manufacture of their oligonucleotide and small molecule medicines now and in the future”.

For further information please contact:

Markus Georgi
Head of Investor Relations
Girindus AG, Member of Solvay Organics
phone: +49-2204-926-900

Kathryn L. Ackley, Ph.D.
Director of Operations
Girindus America, Inc, Member of Solvay Organics
phone: +1-513-679-3070

back to top